Compare iShares MSCI Indonesia ETF (EIDO) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Johnson & Johnson — how do they compare? iShares MSCI Indonesia ETF trades at $12.69, while Johnson & Johnson trades at $261.24 (market cap $626.09B). The key difference: Johnson & Johnson pays a 2.06% dividend while iShares MSCI Indonesia ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.
| EIDO | JNJ | |
|---|---|---|
52-Week High | $19.22 | $267.24 |
52-Week Low | $10.80 | $172.78 |
Market Cap | — | $626.09B |
Volume | — | 6,156,228 |
Sector | — | Health |
Enterprise Value | — | $654.37B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO, the iShares MSCI Indonesia ETF, trades at $12.675, down 0.59% today, with a bearish technical signal from moving averages. The fund's valuation appears low, but financial data for the current period is unavailable. Recent news highlights Indonesia's economic initiatives and central bank policy shifts, while technical indicators show neutral oscillators and defined support at $12.
The outlook is mixed, with potential from Indonesia's GDP growth initiatives but weighed by foreign capital outflows and a strong financials weighting. Risks include currency volatility and dependence on commodity markets. Analyst sentiment is neutral due to weak price action despite attractive valuations.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
